Patents Examined by Changhwa J. Cheu
  • Patent number: 10209247
    Abstract: The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 19, 2019
    Assignee: BioVentures, LLC
    Inventors: Alan J. Tackett, Stephanie Byrum, Sean Taverna, Kevin Raney, Zachary Waldrip
  • Patent number: 10201812
    Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: February 12, 2019
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Eli N. Glezer, Sudeep Kumar, Pankaj Oberoi, George Sigal, Michael Tsionsky
  • Patent number: 10196672
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 5, 2019
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo
  • Patent number: 10197579
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 5, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Gerald Scott Barden Horan, Ying Ye
  • Patent number: 10191048
    Abstract: The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded DNA (dsDNA) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (SLE). The fluorometric immunoassay method for detection of anti-dsDNA solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard Farr-RIA method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%). Detection of anti-dsDNA is based on detection of fluorescence in two fractions of samples, in the supernatant and in the sample with a precipitate, which contains immune complexes composed of added dsDNA and anti-dsDNA present in the patient's serum, wherein the detected fluorescence is a consequence of binding fluorescent dyes with dsDNA bound in the complexes or with free dsDNA.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 29, 2019
    Inventors: Tanja Kveder, Katja Lakota, Tinka Svec, Sasa Cucnik, Polona Zigon, Ales Ambrozic, Snezna Sodin-Semrl, Borut Bozic, Matija Tomsic
  • Patent number: 10184944
    Abstract: The present invention relates to a method for detecting molecules.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: January 22, 2019
    Assignee: The Francis Crick Institute Limited
    Inventors: Banafshe Larijani, Peter Parker, Selvaraju Veeriah
  • Patent number: 10184945
    Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone variants and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone variant biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 22, 2019
    Assignee: BELGIAN VOLITION SPRL
    Inventor: Jacob Vincent Micallef
  • Patent number: 10180433
    Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 15, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
  • Patent number: 10175248
    Abstract: Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 8, 2019
    Assignee: Washington University
    Inventor: Robi D. Mitra
  • Patent number: 10167496
    Abstract: Provided herein and methods and kits for identifying inhibitors of SUMOylation. The provided methods include contacting a candidate agent with (i) a SUMO-conjugating peptide comprising an N-terminal linker and a detectable tag, and (ii) a SUMO comprising a metal complex, under conditions that allow binding between the SUMO-conjugating peptide and the SUMO, and detecting the detectable tag thereby determining the level of binding between the SUMO-conjugating peptide and SUMO. A reduced level of binding as compared to the level of binding in the absence of the candidate agent indicating the agent inhibits SUMOylation.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: January 1, 2019
    Assignee: The UAB Research Foundation
    Inventors: William J. Placzek, Mary-Ann Bjornsti, Christine M. Wright, Robert H. Whitaker
  • Patent number: 10168328
    Abstract: Methods, compositions, and reaction mixtures are provided for identifying a T cell receptor (TCR) and an epitope peptide that specifically binds the TCR. Methods, compositions, and reaction mixtures are also provided for identifying a plurality of T cell receptors and corresponding epitope peptides that specifically bind the T cell receptors. In some cases, the plurality of T cell receptors and corresponding epitope peptides can be identified in a highly parallel manner.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 1, 2019
    Assignee: Roche Sequencing Solutions, Inc.
    Inventor: Jan Berka
  • Patent number: 10168319
    Abstract: This present invention relates to a method for selecting an antigen-specific hybridomas comprising catching a monoclonal antibody secreted from a hybridoma by using a plasma cell's cell-surface expression molecular on the surface of the hybridoma, providing an antigen with a label to react with the hybridoma, and selecting the hybridoma expressing the label to obtain an antigen-specific hybridoma. In other words, the hybridoma can express the label because of the monoclonal antibody combining with the antigen. Accordingly, the method of this present invention can quickly select the antigen-specific hybridoma.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 1, 2019
    Assignee: GREEN ABIOTECHNOLOGY CO., LTD
    Inventor: Chih-Hsuan Lai
  • Patent number: 10161930
    Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: December 25, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch
  • Patent number: 10161942
    Abstract: The present invention provides novel methods for the detection of antibodies, in particular, blood group antibodies. The methods of this invention may be applied to pre-transfusion blood compatibility testing for the detection of incompatibility between donor units (comprising donor red blood cells (erythrocytes)) and a recipient.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: December 25, 2018
    Assignee: QBD (QS-IP) LIMITED
    Inventors: Janine Scott Robb, David Cooper Robson, Neil Kevin Renault, Christopher Robert James Claxton
  • Patent number: 10138508
    Abstract: The present invention provides a method for measuring a modified nucleobase that increases detection sensitivity for the modified nucleobase in a target nucleic acid. Specifically, the present invention provides a method for measuring a modified nucleobase including: (1) incubating a nucleic acid sample, a capture probe, and a guide probe in a solution; and (2) measuring the modified nucleobase using an antibody against the modified nucleobase in the solution obtained at (1). The present invention also provides a kit for measuring a modified nucleobase including: (I) a guide probe; and (II) a capture probe and/or an antibody against the modified nucleobase.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: November 27, 2018
    Assignee: FUJIREBIO INC.
    Inventors: Tatsuki Matsuno, Mariko Horiike
  • Patent number: 10139398
    Abstract: Methods for preparation of cells for analysis of biomarkers are disclosed. In one aspect, the method for preparation of cells for analysis of biomarkers includes contacting a sample that contains a population of cells with at least one modulating substance at a first temperature, thereby producing a modulated cell population; contacting the modulated cell population with at least one antibody that is directed to a cell surface biomarker at a second temperature that is lower than the first temperature, thereby producing an extracellularly stained cell population; and contacting the extracellularly stained cell population with one or more reagents that fixes and permeabilizes the cells, thereby producing a fixed and permeabilized cell population.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 27, 2018
    Assignee: DEEPATH MEDICAL DIAGNOSTICS, INC.
    Inventor: Jita De
  • Patent number: 10138523
    Abstract: The application discloses new biomarkers and methods useful in the diagnosis, prognosis and/or monitoring of, or as a therapeutic or research target for, solid tumor cancers, such as colorectal cancer, based on measuring the biomarkers; and related kits and devices.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: November 27, 2018
    Inventor: Jeffrey Lordan
  • Patent number: 10126310
    Abstract: The present invention relates to methods for determining a binding and/or functional interaction of a protein of interest with a nucleosomal substrate wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern. Further, the invention relates to nucleosomal substrates, wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern, and to methods for providing such nucleosomal substrates.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: November 13, 2018
    Assignee: PROTEROS BIOSTRUCTURES GMBH
    Inventors: Adrian Schomburg, Robert Van Der Burgh
  • Patent number: 10114017
    Abstract: The methods and compositions described herein relate to the measurement of factor VIII (fVIII) levels and/or activity.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: October 30, 2018
    Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Gary Eugene Gilbert, Jialan Shi, Valerie A. Novakovic
  • Patent number: 10114029
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 30, 2018
    Assignee: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann